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Peptide based drugs have been shown to have better target selectivity and thereby better 
safety profile than many small molecule drug candidates. This led many researchers and drug 
companies to show an increasing interest toward bioactive peptides. Developing an effective 
analytical method for peptide /protein structural identification is a cornerstone to meet this 
expanding area of research in this field.   
De novo sequencing is a method of peptide structural identification without using peptide 
databases. Compared to the other de novo sequencing methods, mass spectrometric peptide 
sequence analysis is superior in terms of sensitivity and speed.   
Peptide structural information is contained in the spectrum produced by tandem mass 
spectrometers MS/MS. The quality of the data contained in MS/MS spectra depends on the 
amino acid content of the peptide, the instrumentation and methods used.   
One commonly used peptide fragmentation method is collision induced dissociation (CID) 
where the peptide collides with an inert gas. Depending on the amount of energy applied 
during fragmentation, peptides yield a wide array of product ions. Peptides of known amino 
acid sequence were used to determine the relationship between precursor ion mass-to- 
charge-ratio (m/z) and collision energy needed for optimal peptide fragmentation. The energy 
seems to increase with increasing m/z of the precursor ion. 
A comparison of CID fragmentation methods in a quadrupole-time-of-flight (QTof) 
instrument revealed the merit of using a collision energy ramp compared to single collision 
energy. 
Evaluation of de novo sequencing accuracy of PEAKS software showed that the program 
works well for smaller peptides but the accuracy deteriorates with increasing peptide length.   
The amino acid sequence of an unknown peptide was determined using the PEAKS. The 
software has identified 84 % the amino acid sequences correctly. The rest 16 % of the 
residues were confirmed by Edman degradation. The peptide contained three disulphide 
bridges and identifying cysteine interconnectivity of the peptide is a gap to be addressed in 
the future.  
Key words: Collision energy, ramp, PEAKS, de novo sequencing. 
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Peptide-based therapeutics sector has expanded at the expense of small-molecule drugs in 
recent years. This trend was assisted by the newly popularized availability of recombinant 
protein expression, better protein purification protocols and analysis tools, and the realization 
that peptide based drugs has exquisite potency and selectivity for their molecular targets 
(Góngora-Benítez et al. 2014, Craik et al. 2012). 
Disulfide bridges are posttranslational modifications of peptides and proteins that play a 
pivotal role in the folding and stabilization of their bioactive structures (Morder, 2005). 
Disulphide rich peptide venoms from animals such as snakes, spiders, scorpions and certain 
marine snails represent one of nature’s great diversity libraries of bioactive molecules 
(Ueberheide et al. 2009). This biodiversity can be exemplified by group of small peptides 
called conopeptides, which are widely distributed in the venom of marine mollusks, fish and 
worm-hunting cone snails. It is estimated that more than 50,000 varieties of conopeptides 
exist, out of which only less than 0,1 % of it is pharmacologically characterized (Olivera, 
2006,  Lewis and Garcia , 2003).  
Bioactive peptides have stimulated considerable interest because of their ability to potentially 
alter the function of mammalian ion channels and receptors including nicotinic acetylcholine 
receptors, noradrenaline transporters, sodium and calcium channels (Anand et al. 2014, 
Lewis and Garcia, 2003). Synthesis and structure activity (SAR) studies of these natural 
peptides are presently central to the interest of medical chemistry (Moroder et al. 2005).  
One of the barriers which limit the utilization of this rich resource of bioactive peptides has 
been the difficulty in elucidating their primary structure which ranges in size between 10 and 
80 amino acids (Ueberheide et a.l 2009). Captopril, an angiotensin-converting enzyme (ACE) 
inhibitor, was the first venom-based drug isolated from the Brazilian viper Buthrups 
jararaca. The isolated peptide, teprotide, was de novo sequenced using the Edman 
degradation method (Ondetti, 1971). Ziconotide (calcium channel blocker), bivalirudin 
(thrombin inhibitor) and exenatide (GLP-1 receptor antagonist) are other success stories of 
peptide based drugs (King and Glenn, 2013 Craik, 2012). 
Marine bioprospecting, the systematic search for novel compounds from natural sources in 
the marine environment, has increased rapidly in recent years (Demunshi and Chugh, 2009).  
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In line with this trend the Norwegian government has launched a national strategy entitled 
‘Marine bioprospecting—a source of new and viable wealth creation’’ aimed at promoting 
research within marine natural products and drug discovery. This led to more and more 
Norwegian scientists to be involved in the search for bioactive peptides (Svenson, 2013).  
In Tromsø, research groups working with marine bioprospecting have identified several 
peptides with antimicrobial activity. These peptides are usually sent to other laboratories to 
be sequenced by the Edman degradation method, which is relatively time consuming and 
needs large amounts of sample compared to the MS/MS method. Therefore in order to 
facilitate the growing interest in marine bioactive research, there is a need to locally develop 
an effective analytical method for peptide structural elucidation.   
 
2. Mass spectrometric peptide sequence analysis 
 
De novo sequencing is a method of elucidating peptide primary structure without using 
protein databases (Standing, 2003) where the mass difference between two adjacent ions is 
used to deduce the amino acid sequence of a peptide (Roepstorff, 1984 Tannu and Hemby, 
2007). In the last two decades, most mass spectrometric based protein identification have 
been focusing on searching spectra from mass spectrometry (MS/MS) against protein data 
bases (Liu et al,2014, Westermeier and Naven, 2002, Perkins et al. 1999). 
With the ever-increasing number of complete genomes published, one might think there is 
less need for de novo protein/peptide sequencing. However, protein prediction from genome 
is partly based on availability of genomic sequence from the organism of interest or at least 
from closely related species. But the fact that the genetic information of the vast majority of 
organism is not yet discovered and unpredictability of some post-translational modifications 
make de novo sequencing as relevant as it has been (Liu et al, 2014, Medzihradsky and 
Bohlen 2012, Zhang et al, 2003, Standing, 2003).  
Early de novo sequencing relied on Edman degradation, which combines derivatisation of the 
N-terminal amino acid of a peptide or protein with the subsequent cleavage of the derivatised 
residues. These two steps repeat for each amino acid through the peptide sequence. This 
process is time consuming (one or two peptides per day), work-intensive and needs an 
unmodified N-terminal of peptides. Mass spectrometry (MS) has reduced the need for this 
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technique because it is fast, more sensitive and not affected by N-terminal modifications 
(Westermeier and Naven, 2002). However, the technique is not new since in 1986 Hunt and 
colleagues already described de novo sequencing for the first time, where tryptic peptides of 
apolipoprotein B were successfully sequenced using FAB-triple quadrupole mass 
spectrometry (Hunt et al. 1986). Converting the peptides to gaseous form in the mass 
spectrometer without decomposing the molecules has been the major analytical bottleneck 
(Kinter and Sherman, 2000). Until 1970s, mass spectrometric analysis of organic compounds 
utilized electron impact (EI) ionization methods. In this technique, a radical cation is formed 
from the evaporated sample by expelling an electron. EI is not well suited for analysis of 
polar, in volatile and thermally labile biomolecules (Baldwin, 2005).Introduction of the ‘soft 
ionization’ methods, electrospray ionization (ESI) and matrix-assisted laser desorption 
(MALDI) made mass spectrometry an indispensable tool for protein and peptide analysis 
(Seidler et al. 2010, Baldwin, 2005). These ground breaking ionization methods has earned 
the respective inventers, Koichi Tanaka and John Fenn, the Nobel Prize of 2002. 
In ESI, ionized peptides are formed by spraying diluted solution of the analyte at atmospheric 
pressure from the tip of a fine capillary held at a high electric potential (Baldwin, 2005 Fenn, 
J 2002). In the high voltage capillary, an electrochemical reaction of the solvent leads to the 
formation of a charged droplet (Kebarle and Tang, 1993). The charged droplet will leave the 
nozzle by electrostatic repulsion, and the solvent evaporate while travelling towards the low 
pressure area of the MS to create a continuous stream of gaseous charged analyte which will 
enter the vacuum system (Baldwin, 2005 and Kebarle and Tang, 1993). A schematic 







Figure 1: Schematic representation of the electrospray ionization process (Banerjee and Mazumar, 2011). 
While moving toward the low pressure area of MS, the ionized droplets decrease in size because of the 
solvent evaporation.   Explosion of the droplet due to increasing charge concentration on its surface leads 





Electrospray ionization process does not impart significant amount of energy that can lead to 
unimolecular dissossiation of the ion. But within an intermediate pressure region of the ESI is 
a plate with an aperture commonly referred to as the skimmer or nozzle which accelerate the 
ionized peptides toward low pressure area of the MS. Higher voltage applied to this plate can 
impart high kinetic energy to the ion. When these ions collide with molecules in the air 
within the intermediate pressure area of ESI, the kinetic energy will be converted to 
vibrational energy leading to fragmentation of the peptide (Baldwin, 2005).  
The LC component, which is directly connected to MS, separates the peptides and preventing 
possible sample losses during off-line preparative fractionation (Zhang et al, 2014). For 
positive ionization analysis, typical solvents are acetonitrile or methanol acidified with 1% 
acetic acid or 0.1 % formic acid to ensure the unfolding of proteins and extensive protonation 
of the most basic sites (Baldwin, 2005). 
The ionized peptide is directed to the mass analyzer where the ions are sorted according to 
their m/z ratios. The quadrupole mass filter (Q), the ion trap and the time-of-flight are the 
most commonly used mass analyzers in proteomics (Kinter and Sherman, 2000). 
5 
 
Tandem mass spectrometers (MS/MS) have two mass analyzers where the first mass analyzer 
is used to isolate an ion with a specific m/z (precursor ion) for further fragmentation, and the 
second mass analyzer determines the m/z of the product ions formed from the fragmentation 
of the precursor ion (Matthiesen, 2007   McLafferty, 1981) and can therefore used to obtain 
structural information.  
The use of quadrupole mass analyzer as MS1 and an RF-only quadrupole collision cell in 
combination with an Orthogonal acceleration time-of-flight as MS2 (Figure 2) gives a very 
powerful combination in terms of sensitivity, resolution and mass range (Chernushevich et al, 
2001, Baldwin, 2005).  
                                  
 
Figure-2: A Quadrupole-time–of-flight (QToF) tandem mass spectrometer (Baldwin, 2005). (q0): RF-only 
quadrupole which is used to focus the ionized analyte thereby hindering intermolecular collision (Q): Serves as 
mass filter to select precursor ion of interest for further analysis (q2): Collision cell where the ionized analyte 
collide with inert gases. The product ions are accelerated towards an ion mirror which in turn reflects them back 






 The collision energy usually utilized in MS/MS can roughly be classified as low energy CID 
(< 100 eV) and high energy CID involving up to kilo electron volt kinetic energy (Seidler, 
2010 Wells, 2005). Low-energy collision-induced dissociation (CID) in mass spectrometry 
has been used extensively in peptide sequencing and analysis of post translational 
modifications (PTM) (Zhang et al. 2014 Seidler,2010). 
As shown in the equations below, collisional activation (1) and unimolecular dissociation (2) 
are the two phenomenon assumed to be occurring in CID.   
Q + mp
+ + N → mp
+* + N’      (1) 
where Q is the change in kinetic energy of the system, mp
+ and N are the precursor ion and 
target in their pre-collision states, and mp




+ + mb               (2) 
ma
+ and mb are products of the unimolecular dissociation of mp
+ (McLuckey, 1992).  
 
3.  Peptide fragmentation in MS/MS 
Following collisional activation, the site of protonation directs fragmentation reaction that 
occurs as a means of releasing the excess internal energy added to the peptide ion by the 
collision (Kinter and Sherman, 2000). The fragment ions in CID fragmentation are produced 
primarily by cleavage of the amide bonds that join two amino acids. The analysis of these 
fragments provides sequence information that can be used for de novo sequencing 
(Medzihradszky, 2005). The 20 common amino acids along with their codes and mass are 
given in table 2.  
The nomenclature of product ions was given by Roepstorff and Fohlman for the first time in 
1984 (Roepstorff and Fohlman, 1984). Fragments will be detected only if they carry charge. 
If this charge is retained by the N- terminus fragment, the ion is classified as either a, b or c. 
If the charge is retained on the C- terminus, the ion type is either x, y or z as illustrated on 






Figure 3: Nomenclature of product ions (Roepstorff and Fohlman, 1984). ‘Ri’ represents the amino 
acid side chains of the peptide. Product ions which are formed are termed a, b or c if the charge is 
retained on N-terminus and x, y or z if the charge is retained on the C-terminus. 
 
Generally b, a, y and immonim ions (table-1) are more common in lower energy multistep 
activation spectra, while higher energy activation can additionally lead to the formation of x,y 
and z ions (Wysocki et al. 2005). ). Beside these fragment ions, CID spectra contain neutral 
losses from certain residues of the peptide that can provide sequence information (Seidler et 
al.  2010).  
 
In positive-ion operating conditions, electrospray ionization produces peptide ions that enter 
the mass spectrometer with protons attached to the basic sites. These sites include the N-
terminus amine group, the amide bond and the more basic side group of lysine, arginine, or 
histidine residues (Kapp et al. 2003).  
 
Protons associated with side chains of basic residues are strongly attached and remains fixed 
at that site even on collisional activation unlike protons on less basic N-terminus which may 
move by solvation to any of the amide linkages (Matthisen, 2007 Wysocki et al. 2000). This 
produces a heterogeneous population of the peptide where the proton is associated with an 
amide bond at different sites. This migration of protons along the peptide backbone makes 
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fragmentation reaction to occur at different amide bonds and this process is known as the 
mobile proton effect (Kinter and Sherman, 2000 Wysocki et al. 2000).   
 
QToF mass spectrometers typically yields a series of y-ions throughout the mass range, while 
b-ions are thought to be less stable and fragments further. As a result b-ions are more 
abundant at lower masses and are often absent at higher m/z in the MS/MS spectrum (Katalin 
et al. 2013).  
The accuracy of peptide identification using MS/MS depends on the mass resolution and 
mass accuracy of the instrument, the completeness of the observed fragment ion series and 
the extent to which the fragmentation spectrum can be correctly interpreted (Zhang et al. 




Table 1: Immonium and related ions characteristic of the 20 common amino acids 
________________________________________________________________________ 
Amino Acid Immonium and related ion(s) masses Comments 
________________________________________________________________________ 
 
 Ala   44 
 Arg 129 59, 70, 73, 87, 100, 112 129, 73 usually weak 
 Asn   87 70 87 often weak, 70 weak 
 Asp   88  Usually weak 
 Cys   76  Usually weak 
 Gly   30 
 Gln 101 84, 129 129 weak 
 Glu 102  Often weak if C-terminal 
 His 110 82, 121,123, 138, 166 110 very strong 
    82, 121, 123, 138 weak 
 Ile/Leu   86 
 Lys 101 84, 112, 129 101 can be weak 
 Met 104 61 104 often weak 
 Phe 120 91 120 strong, 91 weak 
 Pro   70  Strong 
 Ser   60 
 Thr   74 
 Trp 159 130, 170, 171 Strong 
 Tyr 136 91, 107 136 strong, 107, 91 weak 
 Val   72  Fairly strong 
________________________________________________________________________ 















Full 3 letter code 1 letter code Neutral molecule (Monoisotopic) 
Alanine Ala A C3H7NO2 71.0372 
Arginine Arg R C6H14N4O2 156.1011 
Asparagine Asn N C4H8N2O3 114.0429 
Aspartic acid Asp D C4H8NO4 115.0269 
Cysteine Cys C C3H7NO2S 103.0092 
Glutamic acid Glu E C5H9NO4 129.0426 
Glutamine Gln Q C5H10N2O3 128.0586 
Glycine Gly G C2H5NO2 57.0215 
Histidine His H C6H9N3O2 137.0589 
Isoleucine Ile I C6H13NO2 113.0841 
Leucine Leu L C6H13NO2 113.0841 
Lysine Lys K C6H14N2O2 128.0949 
Methionine Met M C5H11NO2S 131.0405 
Phenylalanine Phe F C9H11NO2 147.0684 
Proline Pro P C5H9NO2 97.0528 
Serine Ser S C3H7NO3 87.0320 
Threonine Thr T C4H9NO3 101.0477 
Tryptophan Trp W C11H12N2O2 186.0793 
Tyrosine Tyr Y C9H11NO3 163.0633 
Valine Val V C5H11NO2 99.0684 
Source: Medzihradszky, 2012 
 
 
4. PEAKS : A software for de novo sequencing 
 
Manual deduction of amino acid sequences of a peptide from MS/MS spectra is tedious and 
time consuming. In order to address this, a number of algorithms and software packages were 
developed to interpret the data obtained from MS/MS experiments (Pevtsov et al. 2006 Ma et 
al. 2003).  
PEAKS is the most popular software for de novo sequencing showing the best accuracy 
among all currently available program packages (Pevtsov et al. 2006). The software assigns 
two scores fy (m) and fb(m) for each mass m corresponding to a y-ion and a b-ion respectively. 
If the there is a strong intensity peak at mass m (or close to m and within the mass error 
tolerance), then the score is positive. In addition neutral losses that are possibly generated are 
also taken in to account to compute the two score functions (Hughes et al., 2010).  
The software assigns local confidence score for each amino acid which is expressed as 
percent average local confidence (% ALC). The de novo sequencing results can be filtered by 




5. Aims of the thesis 
Main goal 
The main objective of this study is to develop methods for sequencing disulfide rich peptides 
from marine organisms using tandem mass spectrometer.   
Sub-goals 
In order to achieve this goal, we will investigate effects of some mass spectrometric 
parameters (cone potential and collision energy) on peptide fragmentation using model 
peptides of known amino acid sequences.  
Peptides having various amino acid sequence length, amino acid composition and charge 
state will be fragmented at different collision energies to find the relationship between the 
effects of these variables on the choice of an optimal collision energy. The single collision 
energies will also be compared with collision energy ramps in terms of the sequence 
information obtained from the MS/MS spectra. In addition the effect of cone voltage on 
precursor ion intensity will also observed briefly.    
The de novo sequencing potential of PEAKS studio 7 will also be evaluated using peptides of 
known amino acid sequence. 
Finally an unknown bioactive peptide obtained from Norwegian College of Fishery Science 










6. MATERIALS AND METHODS 
 
6.1 Peptides 
Conotoxin-α (GCCSDPRCAWRC-NH2), tertiapine (ALCNCNRIIIPHMCWKKCGKK-
NH2) and neurotoxin (RSCCPCYWGGCPWGQNCYPEGCSGPKV-NH2) were produced 
locally while endothelin-2 (CSCSSWLDKECVYFCHLDIIW), orexin-A 
( pEPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH₂ , where pE stands for             
L-pyroglutamic acid  ) and defensin HNP-1 (ACYCRIPACIAGERRYGTCIYQGRLWAFCC 
were purchased from Bachem AG, Bubendorf, Switzerland.  
 
6.2 Chemicals 
The reducing agent (tris(2-carboxyethyl)phosphine(TCEP) and alkylating agents N-
Cyclohexylmaleimide (NCM), N-Methylmaleimide (NMM) and N-Phenylmaleimide(NPM) 
were obtained from Sigma Aldrich®, Missouri, USA. 
 
6.3 Equipment  
The Waters (Milford, Connecticut, USA) Xevo™ G2 QTof Mass Spectrometer (MS) was 
connected to a Waters ACQUITY UPLC I-class operated by Waters® Masslynx v4.1 
software was used for the MS and MS/MS experiments. The peptides were reduced and 
alkylated on Incubating microplate shaker from VWR®, Radnor, Pennsylvania, USA. 
Analytic scale from Sartorious, Goettingen, Germany was used for weighing of samples.     
C18 (Octadyl) Standard density SPE column from EMporeTM, Minnesota, USA was used as a 
reaction medium when the peptides were selectively reduced and alkylated.    
An online tool, MS-product, was used to generate theoretical m/z of product ions 
http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct  
 
De novo sequencing was done using PEAKS® studio 7 software from Bioinformatics 








7.  METHODS 
7.1. LC methods 
The UHPLC was run by injecting 5 µl (except for the unknown peptide where 10 µl was 
used) sample on to an Acquity CSH C18 (150 x 2.1 mm, 1.7 µm particle size) column 
(Waters, Milford, MA, USA)  at a column temperature of 50 oC. The gradient LC method 
used mobile phases A and B at a flow rate of 0.5 ml/min, where A was 0.1 % formic acid in 
water and B was 0.1 % formic acid in acetonitrile.  
The mobile phase gradient was programmed as follows: 0-6.0 min: 2 – 60% B, 6.0 - 6.1 min: 
60-95% B and 6.10-8.00 min, 95-95 % B. 
 
7.2. MS methods  
Leucine Enkephalin was used as lock spray (m/z 278.1141 Da and 556.2710 Da) with 1sec 
scan time at 15 sec interval. A lock spray contains a compound of known composition used 
by the MS as a reference to avoid a systematic drift in the mass measurement (Cox et al, 
2011).  A cone voltage of 35 V was used throughout the experiments except where the effect 
of cone voltage on the precursor ion intensity was tested. Collision energies used are 
described under respective experiments below, other MS parameters used for all experiments 
are described in table-3. 
 
Table-3: MS Conditions used for all experiments.  
MS Parameters                                                            Values 
Spray Capillary voltage (V)                                                600
Source temperature (oC)                                                     130
Desolvation gas flow rate (l/h)                    800 
Desolvation temperature  (oC )                                      350   
Sample scan time (sec)                                                          0.5  
Collision gas                                                                  Argon 
Ion source polarity                                                           Positive  
Mass range (Da)                                                                  100-5000  
Extraction cone                                                                113.2  
Cone gas flow rate  (l/h)                                             10  
Analyzer mode                                                            Resolution 
Dynamic range                                                            Normal  







7.3. Reduction of the peptides 
In all cases, the model peptides were reduced by incubating 3 µl 0.5 mM peptide with 10 µl   
1 M TCEP and 174 µl 50 mM ammonium formate buffer (pH=3).  The reduced peptides were 
fragmented at collision energies ranging from 20-45eV and sequence ions (b-ions and y-ions) 
identified manually using the online tool, MS-Product. 
The peptides were sequenced by searching the theoretical monoisotopic ions from the 
MS/MS spectrum of the peptide of interest.   Ions of the same charge state and having   m/z 
deviation less than 0.01 Da and intensity higher than 1.00e3 were considered as positive. 
Where possible, neutral losses corresponding to y-ions and b-ions were used to verify the 
findings.   
 
7.4. Effect of cone potential on precursor ion intensity 
In order to determine the effect of cone potential on precursor ion(s) intensity and 
fragmentation pattern, reduced conotoxin-α was subjected to cone voltages (CV) of 20, 25, 
30 and 35 V. After comparing the spectra produced, precursor ions formed at CV 20V and 
CV 35V were fragmented and the peptide sequenced as described under section 7.3.   
7.5. Identifying optimal collision energy (CE) for effective peptide fragmentation 
Peptides of known amino acid sequences were used to establish the relationship between 
mass–to-charge ratio (m/z) of precursor ions and collision energies needed for efficient 
peptide fragmentation.   
Conotoxin-α, tertiapine, endothelin-2, neurotoxin, defensin HNP-1 and orexin-A were used 
as model peptides. The precursor ions with highest charge state were chosen and   fragmented 
at collision energies ranging from 20-45 eV. The sequence ions produced by the different 
CEs were manually identified using the online tool, MS-product. 
For each sequence ion; m/z, charge state and intensity was noted. The collision energy which 
produced maximum number of sequence ions were considered as the optimum collision 






7.6. Comparison of collision energy ramp with optimal single collision energy  
Conotoxin-α, neurotoxin, endothelin-2 and tertiapine were fragmented at collision energy 
ramps of 20-30, 25-35, 25-40 and 30-40 eV. The collision energy ramp that produced the 
maximum number of sequence ions was considered as the optimum collision energy ramp for 
the peptide. In parallel, the peptides were also fragmented with their respective optimal 
collision energies identified in previous experiments. The optimal collision energies and 
optimal ramps were compared based on the number of sequence ions identified.  
 
7.7. Sequence identification of selectively alkylated peptides with two disulphide bridges   
In conotoxin-α (GCCSDPRCAWRC-NH2), C2 is connected to C12 and C3 is connected to 
C8. The two disulphide bridges of conotoxin-α was selectively alkylated by NMM/ NCM and 
NMM/NPM on SPE column following a procedure developed in our laboratory (unpublished 
data). The selective alkylation process has two steps; in the first step one of the disulphide 
bridges is reduced and subsequently alkylated by one of the alkylating agents. In the second 
round the other crosslinking cysteine residues will be reduced and modified by the second to 
alkylating agent. The final result will be the formation of two structural isomers of the 
modified peptide.  
The peptide was fragmented and sequenced to differentiate the two structural isomers. The 









Figure 4: Schematic representation of selective alkylation of conotoxin-α alkylated by NMM and 
NPM. Step 1: Either C3&C8 will be alkylated by NMM or C2 and C12 will be alkylated by NMM. 
Step 2: C2&C12 will be alkylated by NPM and C3 &C8 will be alkylated by NPM to form the 
structural isomers.  
 
 
In order to induce theoretical fragmentation on MS-product C2 & C12, which are connected 
to each other, were labeled by a letter (u) and C3&C8 are labeled by v.  
 
7.8. Evaluating the accuracy of PEAKS Studio 7 software 
In order to evaluate the accuracy of the PEAKS software, peptides of known amino acid 
sequence having different precursor ion m/z, charge state and peptide sequence length was 
selected. conotoxin-α (12 residues), endothelin (21 residues), neurotoxin (27 residues) and 
defensin HNP-1 (30-residues) were selected.  
Prior to data entry, spectra having higher intensity of product ions in all m/z areas were 
chosen. In all the cases, precursor ion and fragment ion error tolerance of 0,005 Da was used.  
After the de novo sequencing has run on the software, theoretical fragmentation was induced 
on MS-product for the suggested peptide sequence. Manual evaluation of the result was done 
by searching the theoretical fragment ions in the spectrum.  Only amino acid sequence 




7.9. De novo sequencing of the unknown peptide 
The unknown peptide for de novo sequencing was obtained from The Norwegian College of 
Fishery Science. After dissolving the sample in 50mM ammonium formate (pH=3), the 
molecular weight of the peptide was identified using MS.  
The peptide was incubated with freshly prepared 1 M TCEP to reduce the peptide. After the 
numbers of disulfide bridges were identified, a precursor ion was selected and fragmented by 
single collision energies of 35 and 40eV and collision energy ramps of 25-45 and 35-55 eV. 
The product ions of the spectra in all m/z areas were compared based on their intensities. The 
spectrum of good quality (higher product ion intensities in most of the areas) was chosen for 
de novo sequencing.    
The peptide was sequenced using PEAKS by choosing precursor ion and product ion mass 
error tolerance of 0.005 Da. The result was carefully validated by searching theoretical 
fragment ions of the suggested sequence in the MS/MS spectrum.    
Neutral losses and mass deviation were also taken in to consideration in verifying the 














8. RESULTS AND DISCUSSION 
 
8.1 Effect of cone voltage on precursor ion intensity 
Mass spectra of conotoxin-α at cone voltage (CV) of 35 V revealed intact peptide ion, 
[M+2H] 2+= 678.2632, and two fragment ions [y7
2+ = 445.7216 and y10
2+ = 598.2498] with 
significant intensities. After the CV was reduced to 20 V, the charge state of the precursor ion 
was shifted more towards [M+3H] 3+= 452.5224 and fragmentation of the peptide was found 




Figure 5: Mass spectra of conotoxin-α at CV 35 V and 20 V.  a) Spectrum at CV 35 V showing low 
intensity of [M+3H] 3+ and relatively high intensity of [M+2H] 2+ and fragment ions.  b) At cone 




As discussed earlier  in the theory part, the potensial that accelerates the ionized peptides 
towards the low pressure area of the mass spectrometer can cause fragmentation of the 
peptide (Balwin, 2005). Similarly,the decreasing charge state of the ionized peptide wih 
increasing CV is probabily due the collision between the ionized peptide and molecules in the 
air within intermediate pressure area of the mass spectrometer which can strip off the losely 
bound protons. 
The precursor ions,  [M+2H]2+ = 678.2632 and  [M+3H]3+ = 452.5224,  obtained at CV of  
35V and 20 V, respectively were   fragmented at collision energies  ranging from 20 eV to 40 
eV.  The ion [M+3H]2+ produced fewer sequence ions at CE under 30 eV as shown in table 4.  
 
Table-4: Observed sequence ions of Conotoxin-α fragmented at CV 20V and 35 V and CE between 
20eV and 40 eV. At CV 35 and collision energies between 30 to 40 eV, sequence information about S 
and D was not found because of the missing y8/b4-ions. Reduction of the cone voltage to 20 V led to 
the appearance of the y8 2+ ion at 20eV. 
Conotoxin-α [M+2H] 2+ = 678.2811  CV  35V 
25eV 30 eV 35 eV 40eV b-ions  y-ion 25eV 30 eV 35 eV 40eV 
    1 G 12     
  (+1)  (+2)  (+1) 2 C 11     
  (+1)  (+2)  (+1) 3 C 10     
    4 S 9     
 (+1)    5 D 8     
    8 P 7  (+2)  (+2)  (+2)  (+1) 
    7 R 6   (+2)  (+2)  (+1) 
    8 C 5  (+1)  (+1)  (+1)  (+1) 
  (+1)   9 A 4   (+1)  (+1)  (+1) 
  (+1)   10 W 3   (+1)  (+1)  (+1) 
 (+2)  (+2)   11 R 2   (+1)  (+1)  (+1) 
    12 C 1   (+1)  (+1)  (+1) 
Conotoxin-α [M+3H] 3+ = 452.5218  CV 20V  
 
20 eV  25 eV 30 eV b-ions  y-ions 20 eV  25 eV 30 eV 
   1 G 12      
 (+1)  (+1)  (+1) 2 C 11  (+2)   
 (+1)  (+1)  (+1) 3 C 10  (+2)  (+2)  
 (+1)   4 S 9  (+2)   
 (+1)   5 D 8  (+2)   
   6 P 7  (+2)  (+2)  (+2) 
   7 R 6  (+2)  (+2)  (+2) 
   8 C 5  (+1)  (+1)  (+1) 
   9 A 4  (+1)  (+1)  (+1) 
   10 W 3  (+1)  (+1)  (+1) 
   11 R 2  (+1)  (+1)  (+1) 






In charged R containing peptides, protons are tightly bound to the basic side chain of the 
amino acid. In order to transfer the protons from amino acid side chain to the peptide 
backbone, energy will be needed (Kapp et al. 2003 Wysocki et al. 2000). In agreement with 
this theory, conotoxin-α of two charge state needed extra energy to mobilize the protons.     
Fragment ions of [M+3H]3+ cover almost the complete sequence ions at collision energy of 
20eV this is most probably due to  the lower m/z of the precursor ion and the extra charge 
which can freely move along the peptide backbone and induce charge directed dissociation. 
This finding indicates that the sequence information obtained from peptide fragmentation can 
be improved by adjusting the cone voltage.    
 
8.2 Determination of optimum collision energy for peptide fragmentation 
Mass-to -charge ratio (m/z) and charge state of precursor ions are the two main details 
obtained by an investigator at the early stage of a de novo sequencing experiment. Before one 
embarks on fragmenting the peptide of interest choosing appropriate collision energy is a 
crucial step.  An attempt was done to establish the relationship between m/z and collision 
energy needed to effectively fragment a peptide. 
Identified sequence ions of conotoxin-α, tertiapine, endothelin-2, neurotoxin, defensin HNP-1 
and orexin-A fragmented at CEs between 20eV and 40eV are shown in appendix 1.  
Tertiapine (z = 4) has produced large number of sequence ions when fragmented with 
collision energies 20eV and 25 eV. For energies higher than 25 eV the number of sequence 
ions diminishes and product ions are more concentrated at the lower m/z range of the 
spectrum. The same phenomenon was observed for conotoxin-α (z = 3) and it is assumed that 
the added extra energy over the optimal collision energy may have induced internal 
fragmentation of the peptide and thereby reduced the intensities of the sequence ions.  
Collision energies that produced the maximum number of sequence ions of the peptides 




Figure 6: Optimum collision energies plotted against m/z of the precursor ions. Precursor ions at m/z under 600 
tend to fragment sufficiently at collision energies between 20-30 eV. For precursor ions between m/z 600 -1000, 
collision energies between 30 and 40 eV seem to produce good fragmentation. 
 
The CE needed for optimal fragmentation of the peptide increased with increasing precursor 
ion m/z, but raising the collision energy over 40 eV was associated with lower number of 
sequence ions. Factors such as precursor ion charge state and amino acid composition of the 
peptide can have a dramatic effect on the formation of sufficient fragment ions to enable 
subsequent identification of the peptide (Kapp et al, 2003). Therefore considering only m/z to 
determine an optimal collision energy might be an over simplification of the subject matter. 
Even if the number of tested peptides and factors considered were limited this preliminary 
study can give some hint as to which collision energy to choose in order to obtain a 
reasonable fragmentation.   
  
8.3 Comparison of collision energy ramp with optimal single collision energy 
After the peptides were fragmented by collision energy ramps of 20-30 eV, 25-35 eV and 25-
40eV, a ramp that produced a maximum number of sequence ions was selected as an optimum 
ramp for that particular peptide. 
The optimum collision energy ramps of the peptides were also compared with the 
corresponding optimum single collision energy based on the number of sequence ions 






























Table-5: Summary of optimal single collision energies and optimal collision energy ramps 
determined for each peptide. Conotoxin-α, endothelin-2 and neurotoxin the peptides fragment well 
with CE between 30 and 40 and the average value was used as optimal CE. 





Conotoxin-α 452.5218 3 20 20-30 
Tertiapine 615.3226 4  25 25-35 
Conotoxin-α 678.2739 2  35 25-40 
Endothelin 850.7051 3 35 25-40 
Neurotoxin 979.3962 3 35 25-40 
 
The table clearly indicates that the choice of ramp scan is also related to the precursor ion 
mass-to-charge ratio.  
Appendix-2 shows identified sequence ions of conotoxin-α, endothelin-2, neurotoxin and 
tertiapine after the peptides were fragmented by their respective optimum single collision 
energies and optimum collision energy ramps. In almost all of the cases, the number of 
sequence ions produced by the ramp modes were equal to or greater than the number of 
sequence ions formed by the optimum single collision energies. 
Effect of collision energy ramp can also be illustrated by the fragmentation pattern of 
modified conotoxin-α where the cysteine residues were alkylated by the N-methylmaleimide 
(NMM). The identified sequence ions showed four distinct areas as indicated in table 6 where 
fragment ions at higher m/z were observed at lower CE (20-30 eV) and fragment ions at lower 
m/z were observed at higher CE (35-40eV). After fragmenting the peptide with ramp mode 






Table-6: Identified sequence ions of Conotoxin-α alkylated by N-methylmaleimide (NMM) at 
different collision energies. Numbers in the bracket indicate charge state of the fragment ions. Using 
the ramp modus almost all the sequence ions was identified, all the ions were y-ions.  
Conotoxin-α / NMM [M +3H] 3+= 600.5555 




20 eV 25eV 30eV 35eV 40eV RAMP  
             25 - 35 
eV 
    (+1) (+1)  (+1) 1 G 12            
(+1) (+1) (+1)     2 C 11 (+2) (+2) (+2)       
(+1)   (+1)   (+1) 3 C 10 (+2) (+2) (+2)     (+1) 
    (+1)     4 S 9 (+2) (+2) (+2)     (+1) 
  (+1)       5 D 8  (+2)         
          6 P 7 (+2) (+2) (+2) (+2)   (+1) 
          7 R 6    (+2) (+1)  (+1) (+1) 
          8 C 5 (+2)   (+1) (+1) (+1) +1) 
          9 A 4      (+1) (+1) (+1) 
          10 W 3 (+2)     (+1) (+1) (+1) 
          11 R 2       (+1) (+1) (+1) 















8.4.  Sequence identification of selectively alkylated peptides with two disulphide 
bridges   
 
Conotoxin-α was selectively alkylated by N-Cyclohexylmaleimide (NCM) and N-
Methylmaleimide (NMM) on Solid phase extraction (SPE) columns.     
The MS/MS chromatogram of the selectively alkylated conotoxin-α formed two separate 
peaks (A, B) in both cases as shown in figure 7.  
 
Figure 7: Chromatograms of selectively alkylated conotoxin-α. 1) The peptide was alkylated by NMM and 
NPM. The two isomers of conotoxin-α has formed two peaks, A and B. In A, C2&C12 were modified with 
NMM while C3 &C8 were by NPM. In B, C2&C12 were alkylated by NPM while C3&C8 were modified with 
NMM. The two peaks were not completely separated which can be due to the short retention time. 2) The 
peptide was alkylated by NMM and NCM. Peak A: C2&C12 are alkylated by NMM while C3&C8 are alkylated 
by NCM. Peak B: C2&C12 are alkylated by NCM and C3&C8 are alkylated by NMM. The two peaks of A 
produce similar sequence ions which may show the two peaks of A are rotamers. 
 
The two peaks of the MS/MS chromatogram of conotoxin-α alkylated by NMM and NPM 
were sequenced separately. In the first peak (A) C2 and C12 were found to be alkylated by 
NMM while C3 and C8 were alkylated by NPM. In the second peak (B), the MS/MS 
spectrum revealed C2 and C12 are bound to NPM while C3 and C8 are to NMM. The 
identified sequence ions are presented in appendix 3. 
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Similarly structural isomers of conotoxin-α were identified using MS/MS spectrum obtained 
from A and B of the second chromatogram in above figure. 
In addition sequencing the two peaks of A (2), yielded similar residue sequence which may   
indicate that the two peaks of A are most likely rotamers.   
Sequence ions between y1-y4 and y10 were used to differentiate the two structural isomers as 
indicated in appendix 3.   
8.5. Evaluation of the potential of Peaks Studio 7 software for de novo sequencing 
According to the manufacturer of the software, the performance of PEAKS is dependent on 
the quality of the spectrum selected for the de novo sequencing. In order to minimize the 
confounding effect of the spectral quality, MS/MS data produced at optimum collision 
energies/ramps from the previous experiments were used.  
Sequencing of conotoxin-α, endothelin-2, neurotoxin and defensin using PEAKS has shown 
various accuracy levels.   
As previously discussed under section 8.1, manual sequencing of conotoxin-α fragmented at 
CV 20 V and CE 20eV has identified almost all the sequence ions of the peptide.    
Automated sequencing using PEAKS has also identified the sequence of the peptide with      
% ALC of 91 as shown in figure 7 below.  
 
 
Figure 8: Annotated MS/MS spectrum of conotoxin-α. The PEAKS software has correctly identified the amino 




The identified amino acids at the N-terminal, GC, are ambiguous because of the missing y11- 
ions from the spectrum. In the same way, the software didn’t clearly determine whether y3 is 
–WRC or -ARC. This can be confirmed by looking for the theoretical values of y3/b9 of     
sequences, GCCSDPRCAWRC-NH2 and GCCSDPRCWARC-NH2 in the MS/MS spectrum.    
In this case, only the y3-ion (m/z = 463.2234) of the former sequence was identified in the 
spectrum proving its correctness. 
The other peptide that has been sequenced by PEAKS was endothelin-2 fragmented at 
collision energy ramp between 25eV and 40 eV. With manual sequencing, y7/b14 was 
missing in the MS/MS spectrum as shown in appendix 2.The sequencing result from the 
PEAKS software shows two areas of the peptide which were incorrectly assigned, the two 
residues of the N-terminus and the three residues DRT in the middle of the peptide as shown 






















Figure 9: Amino acid sequence (A) and ion table (B) of endothelin-2 as assigned by PEAKS. The 
correct sequence of endothelin-2 is CSCSSWLDKECVYFCHLDIIW. The sequences were 





Assuming the peptide sequence is unknown, it can be challenging to identify the correct order 
of the two N-terminal residues since both b1 and y20 are missing from the spectrum. For the 
other incorrectly labelled residues, DRT, it is possible to confirm whether the suggested 
sequence is correct or not by going through the spectrum manually.  
The three residues can be arranged in 6 different ways:-DRT- , -DTR- , -RDT- , -RTD- , -
TRD- and TDR.  
As a result, b8 can have three different values: SCCSSWLD- (b8
1+, m/z = 882.3121), 
SCCSSWLR-(b8
1+ = 923.3862 or b8
2+ = 462.1967) and SCCSSWLT- (b8 
1+ = 868.3328).  By 
searching these theoretical m/z values in the MS/MS spectrum we can see a high intensity ion 
at m/z 882.3130 with mass deviation below 0.01 Da for the first alternative. But for the other 
two possible sequences, both the b-ions and their corresponding y-ions are missing from the 
MS/MS spectrum. Still this may not prove the correctness of the sequence since two amino 
acids can be isobaric (e.g. I =L) or two amino acids can have the same mass as a single amino 
acid (e.g. GG = N) as shown in table-7. Because there are no residue(s) which have the same 
mass as D, one can positively conclude the presence of D at that site.     






SCCSSWLDTRCVYFCHLDIIW (b1+ = 983.3597, y12
1+ =1567.7548/ y12
2+ = 784.3811). 
There are no m/z values in the spectrum that correspond to these sequence ions but b10 
1+ is 
present in the spectrum at m/z =1139.4572. Therefore we cannot confirm whether R and T are 
found in the peptide or not. According to table 7 RT has a mass of 257.1488 and other 
residues which have a mass close to this value (257.1376) is KE. Therefore if RT is replaced 
by KE, b9 1+ can be found at m/z = 1010. 4070 with fairly high intensity. 
In this case even if the ion is found in the MS/MS spectrum, the software didn’t recognized 
the ion. This kind of error can only be discovered by manual evaluation of the sequencing 
output therefore it is very important to go through the actual spectrum confirm the presence of 






PEAKS has also correctly identified the sequences of tertiapine which has 21 residues. But for 
neurotoxin (27 residues) fragmented by collision energy ramps between   25eV and 40 eV, 
only residues between y1 and y17 were identified correctly (data not shown). As shown in 
appendix 2, manual sequencing has identified almost all the sequence ions except b5/y22. 
This might indicate the de novo sequencing accuracy of the software is dependent also on the 
length of the peptide. Therefore for larger peptides, one has to consider digesting the peptide 
in order to obtain accurate amino acid sequence.  
The software has also failed to sequence defensin-HNP1 which has 31 residues but in this 
case even with manual sequencing few sequence ions were recovered from the MS/MS 
spectrum. Therefore the failure of the software to sequence defensin- HNP1 can attributed to 


















Table 7 : Masses of amino acid residues in a peptide sequence.   
 









8.6  De novo dequencing of a bioactive peptide  
 8.6.1. Mass spectrometry of the unknown peptide (ppt1) 
The MS  chromatogram of the smaple obtained from Norwegian College of Fishery Science 
(NCFC) revealed the presence of two major peaks labeled 1 and 2 in figure 10 and m/z of the 
major peptides found under each peak is given in the table.       
 
Figure  10:  Mass spectrometery of the sample obtained from NCFS reveals at two major 













After the peptide is reduced, the MS chromatogram showed two peaks labled A and B which 
are not completely separated as shown in figure 11.  
 
 
Figure 11: Chromatogram of the reduced peptide displaying two peaks which are not completely separated, A 
&B. (A) mainly contains a peptide,  [M+2H]2+ = 1022.8788, which will be referred to as ppt1 in the text.  (B) 
Also contains a relatively intense peptide, [M+2H] 2+ = 1023.3720, labeled ppt2. The m/z difference between 
ppt1 and ppt 2 is 0.5.  
 
The first peak of the above chromatogram contains an abundant peptide (ppt1)  with m/z = 
1022.8788 and this peptide had m/z value of 1019.8369 in its oxidized form. Similarly m/z of 
pp2 has also increased from 1020.3416 to 1023.3720 when reduced. This indicates both ppt1 









8.6.2. Tandem mass spectrometry of ppt1 
Because of its high abundance in the mixture and prior information we have from NCFC 
about its biological activity, ppt1 was selected and fragmented for de novo sequencing.   
The MS/MS chromatogram of ppt1 shows two peaks, C and D. Tailing of ppt1 (C) comes out 
with peak of ppt2 (D) as indicated in figure 12 below.  This is due to the fact that the m/z 
difference between ppt1 and ppt2 with two charge state is only 0.5 and the instrument cannot 
discriminate the ions during ion selection because of the close m/z values. 
 
Figure 12:  The MS/MS chromatogram of ppt1 showing two peaks, labelled C and D. Tailing from 
peaks C comes out with peaks of D.  
 
The fact that ppt1 and ppt2 have so close retention time may suggest that they have some 
common structural features. In addition, gross comparison of the MS/MS spectra extracted 
from the two peaks (C&D) of the chromatograms shows very similar product ions in all areas 
of the spectra as shown in figure 13.  
One structural commonality which can lead to this phenomenon is if ppt1 and ppt2 have the 










Figure 13: Spectra showing product ions extracted from the two peaks in the MS/MS chromatogram.   (C) & (D) refers to the peaks of the chromatogram they 
extracted from (See also figure-12 above).
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8.6.3 De novo sequencing of ppt1 using PEAKS Studio 7 software.  
The MS/MS data of ppt1 in figure-13C shows ions at m/z 120.0809, 129.0647 and 136.0766 
which indicates the presence of Phe, Arg and Tyr, respectively.   
Because of the mass difference (1Da), close retention time and similarity in MS/MS product 
ions of ppt1 and ppt2, it was assumed that ppt1 is an amidated form of ppt2.  
The data entry for the de novo sequencing was done by choosing retention times between 4.09 
– 4.16 min, post translational modification (PTM) parameter ‘amidated’ and ion mass error of 
0.005 Da.  
The de novo sequencing of ppt1 at percent average local confidence (% ALC) of 86 is shown 
in figure 14.   
 
Figure 14: Automated de novo sequencing output of ppt1.  The amino acids y1- y8 were identified 
with high confidence while the orders of CR and –GWCYGF- were not precisely determined. 
 
The other candidates suggested by PEAKS having ALC greater than 50 % were: 
CCGWCYGFCRLTNAQCCD (% ALC 69)  
CCWGCYGFFARPNDCCNS (%ALC 52)  
QDCCCYGFTSALVWECCD (% ALC 52). 
For the suggested amino acid sequence of ppt1 at % ALC of 86, theoretical fragmentation was 
induced on Mass-product. The theoretical and observed m/z of sequence ions, mass deviation 
and intensity of the sequence ions are presented in table-8.    
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Table 8: Theoretical and observed m/z of fragment ions from the de novo sequencing output of ppt1. Many of the b-














--- 104.0177  357 1 C 18 ---    
207.0256 207.026 -0.0004 4.28e4 2 C 17 1941.7321    
264.0471 264.0529 -0.0058 1.06e3 3 G 16 1838.7230    
450.1264 450.11 0.0164 3.23e4 4 W 15 1781.7    
553.1356 553.1234 0.0122 3.67e4 5 C 14 1595.62    
716.1989 716.1804 0.0185 8.59e3 6 Y 13 1492.61    
773.2204 773.2045 0.0159 5.60e3 7 G 12 1329.55 1329.5465 0.0032 3.22e4 
920.2888 920.2645 0.0243 2.77e3 8 F 11 1272.53 1272.5194 0.0088 5.34e3 
1023.298 1023.3062 -0.0082 1.42e3 9 C 10 1125.46 1125.4495 0.0103 1.34e4 
1179.3991 1179.3936 0.0055 1.35e4 10 R 9 1022.45 1022.454 -0.0034 6.91e3 
1292.4832 1292.4722 0.011 1.46e4 11 L 8 866.35    
1391.5516 1391.5215 0.0301 3.65e4 12 V 7 753.265 753.2664 -0.001 1.52e3 
1506,5785 1506.5652 0.0133 2.67e4 13 D 6 654,197 654.1927 0.0043 4.37e3 
1620,6215 1620.5947 0.0268 6.07e3 14 N 5 539,17 539.1656 0.0045 3.80e3 
1723,6306 1723.618 0.0126 5.71e3 15 C 4 425,127 425.1257 0.0015 4.43e3 
1826,6398 1826.6534 -0.0136 4.20e3 16 C 3 322,118 322.1192 -0.0012 8.2e3 
1940,6828 1940.6692 0.0136 317 17 N 2 219,109 219.1096 -0.0008 2.25e4 
---    18 S 1 105,066 105.0654 0.0005 1.04e4 
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All the sequence ions are found in the spectrum with reasonably high intensity. But many of 
the b-ions show fragment ion mass errors greater than 0.01 unlike the y-ions. We can also see 
that the deviation starts from b4 where the observed value is less than the expected value. This 
might suggest W might be incorporated incorrectly. 
According to table 7, the mass of W is 186.0793 Da, which is close to the combined mass of 
AD and EG (186.0641 Da and 186.0640 Da, respectively). In addition, W which usually 
produces a strong immonium ion (Medzihradszky, 2005) is not present in the lower mass 
range of the MS/MS spectrum. Absence of an immonium ion from a spectrum doesn’t mean 
the residue is not present in the peptide (Medzihradszky, 2005) but it can build on the 
previous suspicion that one or more incorrect amino acids are present in the sequence. 
After replacing W by AD and inducing theoretical fragmentation on Mass-product, m/z   
deviations from the theoretical values for the identified b-ions fall below 0.01 as shown in 
















 Table 9: Theoretical and observed m/z sequence identified by PEAKS at % ALC 86 after W is replaced 














--- 104.0177   357 1 C 19 ---       
207.0256 207.026 0.0004 4.28e4 2 C 18 1941.7169       
264.0471 264.0529 0.0058 1.06e3 3 G 17 1838.7077       
335.0842           4 A 16 1781.6862       
450.1112 450.11 -0.0012 3.23e4 5 D 15 1710.6491       
553.1204 553.1234 0.003 3.67e4 6 C 14 1595.6222    
716.1837 716.1804 -0.0033 8.59e3 7 Y 13 1492.613    
773.2051 773.2045 -0.0006 5.60e3 8 G 12 1329.5497 1329.5465 0.0032 3.22e4 
920.2736 920.2645 -0.0091 2.77e3 9 F 11 1272.5282 1272.5194 0.0088 5.34e3 
1023.2827    10 C 10 1125.4598 1125.4497 0.010 1.34e4 
1179.3839 1179.3936 0.0097 1.35e4 11 R 9 1022.4506 1022.454 -0.0034 6.91e3 
1292.4679 1292.4722 0.0043 1.46e4 12 L 8 866.3495    
1391.5363    13 V 7 753.2654 753.2664 -0.0010 1.52e3 
1506.5633 1506.5652 0.0019 2.67e4 14 D 6 654.197 654.1927 0.0043 4.37e3 
1620.6062    15 N 5 539.1701 539.1656 0.0045 3.80e3 
1723.6154 1723.618 0.0026 5.71e3 16 C 4 425.1272 425.1257 0.0015 4.43e3 
1826.6246    17 C 3 322.118 322.1192 -0.0012 8.2e3 
1940.6675 1940.6692 0.0017 317 18 N 2 219.1088 219.1096 -0.0008 2.25e4 
---       19 S 1 105.0659 105.0654 0.0005 1.04e4 
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Because of the low mass error AD/EG can be the most likely residues at that site instead of 
W. Since the ion b5 of CCGADCYGFCRLVDNCCNS-NH2 and CCGDA 
CYGFCRLVDNCCNS-NH2 have the same m/z we can searched for the b4-ion in the 
spectrum to identify the correct sequence.  
If the second sequence is correct, the value of b4
1+ = 379.0741 or y15 
1+ = 1666.6593/             
y15 
2+ = 833.8333 will be found in the spectrum, but the search gave no result. Following the 
same procedure, no ion corresponding to m/z of b4 or the corresponding y-ions were found 
using the first sequence option, CCGADCYGFCRLVDNCCNS-NH2.  
The other residues which have combined mass similar to W is -EG-. After following the same 
procedure to find the value of b4 in the spectrum for sequences; CCGEG- and CCGGE, none 
of the values were found. This leaves us with an unconfirmed residue sequence, W. 
Looking at the local confidence level of the residues on PEAKS, G has a value of 34 % which 
is much lower than the values assigned to other amino acids (where all the residues got 
confidence score >70%). 
Based on the low confidence score assigned to G and the uncertainty associated with W, one 
can certainly suspect that –GW- in the sequence might be incorrectly assigned.  
Continuing with the rest of the sequence,  




2+ = 746.8101), CCGADY- (b6
1+ = 613.1745 
or y13
1+=1432.5589/ y13 
2+= 716.7831), CCGADG- (b6
1+ = 507.1326 or   y13 1+ =1538.6007/ 
y13 
2+ = 769.8040) and CCGADF- (b6 
1+ = 597.1796 or y13 1+ = 1448.5538/y13 2+ =724.7805). 
Since we know b6 
1+ of CCGADC is present, we will look for ions of the other possible 
sequences.  After searching for all the ions none of them were found, this confirms the 
correctness of the sequence up to b6.  In the same way b7 will have three possibilities, b8 has 
two possibilities. Repeating the same process existence of these residues was manually 
confirmed.  
PEAKS also didn’t identify how –C- and -R- are arranged relative to each other (CR or RC) 
and we will manually go through the spectrum to find the possible correct sequence. If we 
start from CCGADCYGFCRLVDNCCNS-NH2, the m/z value b10 
1+ = 1022.4540 is found in 
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the MS/MS spectrum unlike b10 of the other alternative. Therefore we finally come to the 
conclusion that the most likely   sequence of ppt1 is as shown in figure-15. 
  
 
Figure 15:  Possible amino acid sequences of ppt 1 after manual and automated sequencing. The 
residue G was manually found in MS/ MS spectrum but the local confidence score assigned to it very 
low (34%). Existence of –AD- not confirmed.   
 
The peptide ppt1 was also sequenced by removing the post translational modification (PTM) 
parameter, amidation, during the data entry keeping all the other parameters (ion error, 




Figure 16: Annotated MS/MS spectrum and alignment of ppt1 after the PTM parameter was removed 
holding all the other parameters constant.  
 
This amino acid sequence was identified as the second candidate having % ALC 69 when 
PTM parameter, amidated, was used as indicated earlier. 
The theoretical m/z, the observed masses, mass deviation and intensities of the identified ions 
are given in table 10. 
18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
y-ions
C C G A D C Y G F C R L V D N C C N S NH2
b-ions
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
40 
 











Mass error Intensity 
---       1 C 19 ---       
207.0256 207.026 -0.0004 4.25e4 2 C 18 1941.7169       
264.0471 264.0527 -0.0056 1.00e3 3 G 17 1838.7077       
335.0842     4 A 16 1781.6862       
450.1112 450.11 0.0012 3.22e4 5 D 15 1710.6491       
553.1204 553.1235 -0.0031 3.63e4 6 C 14 1595.6222       
716.1837 716.1805 0.0032 8.54e3 7 Y 13 1492.613       
773.2051 773.2045 0.0006 5.60e3 8 G 12 1329.5497 1329.5465 0.0032 3.20e4 
920.2736 920.2643 0.0093 2.75e3 9 F 11 1272.5282 1272.5193 0.0089 5.29e3 
1023.2827       10 C 10 1125.4598 1125.4495 0.0103 1.36e4 
1179.3839 1179.3934 -0.0095 1.34e4 11 R 9 1022.4506 1022.4545 -0.0039 6.83e3 
1292.4679 1292.4722 -0.0043 1.46e4 12 L 8 866.3495       
1393.5156       13 T 7 753.2654 753.2664 -0.001 1.52e3 
1507.5585 1507.551 0.0075 1.46e4 14 N 6 652.2178       
1578.5956       15 A 5 538.1748       
1706.6542       16 Q 4 467.1377 467.1388 -0.0011 1.21e3 
1809.6634       17 C 3 339.0791 339.0784 0.0007 4.47e4 
1912.6726       18 C 2 236.07 236.0689 0.0011 7.50e3 
---       19 N 1 133.0608 133.0611 -0.0003 5.31e4 
 
Absence of b13/ y 6 leads to unconfirmed sequence of TN, in addition to GAD. Both de novo 
sequencing results of ppt1 show similar amino acid sequences between b1-b12 and the C- 
terminal – CCN- part. These facts may indicate the N-terminus of ppt1 is actually amidated. 




















The correct sequence of the peptide after Edman degradation was found to be 
CCDQCYGFCRLVDNCCNS-NH2, and 84 % of the amino acid sequence was correctly 
assigned by PEAKS software. Ions corresponding to –DQ-, b3
1+ (322.0535, at intensity of 
5.11e4) and b4 
1+ (450.11 at intensity of 3.23e4) are found in the spectrum.   
 
As mentioned in the previous discussion, residues –GAD- were not confirmed positively under 
the manual evaluation. Other residues having the same mass as –GAD- include NE, DQ and 
EGG. These residues were not considered under the manual evaluation by erroneously thinking 
G was the correct residue.  
The correct sequence could have been confirmed by searching the b3 values of: CCNE- (b3
1+ 
=321.0686), CCEN- (b3 
1+ = 336.0682), CCQD- (335.0842), CCDQ- (b3 
1+= 322.0526). The first 
three are not found in the MS/MS spectrum this implies, it is DQ which is found at the site 
instead of W.  
Therefore when using PEAKS as a de novo sequencing tool, it is very important to see the results 
in terms of the residue local confidence scores. In addition, for ambiguously assigned sequence 
segments, it is mandatory to consider each and every amino acid combination to look for the 
correct residue at the site. 
Neutral losses obtained from MS/MS for the correct sequence of ppt1 are presented in table 11. 
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Table 11: Neutral losses from the sequence ions of ppt1   
ion m/z ion m/z ion m/z m/z b  
y m/z ion m/z ion m/z ion m/z 
            --- 1 C 18 ---             
        a2 179.0307 207.0256 2 C 17 1941.7169             
        b3-H2O 304.0420 322.0526 3 D 16 1838.7077             
b4-NH3 433.0846 b4-H2O 432.1006 a4-NH3 405.0897 450.1112 4 Q 15 1723.6808             
b5-H2O 535.1098 b5-NH3 536.0938 a5-NH3 508.0989 553.1204 5 C 14 1595.6222             
    a6-NH3 671.1622 a6 688.1888 716.1837 6 Y 13 1492.6130 y13-H2O 1474.6024         
b7-NH3 756.1786 b7-H2O 755.1946 a7-NH3 728.1837 773.2051 7 G 12 1329.5497             
b8-H2O 902.2630 b8-NH3 903.2470 a8 892.2786 920.2736 8 F 11 1272.5282             
  
      
    1023.2827 9 C 10 1125.4598 y10-NH3 1108.4332 a10 1151.3889 
    
        b10-NH3 1162.3573 1179.3839 10 R 9 1022.4506 y9-NH3 1005.4241         
        a11 1264.4730 1292.4679 11 L 8 866.3495             
    b12-NH3 1374.5098 a12 1363.5414 1391.5363 12 V 7 753.2654 y7-NH3 736.2389         
        b13-NH3 1489.5367 1506.5633 13 D 6 654.1970 y6-H2O 636.1865 b6-H2O 698.1731 y6-NH3 637.1705 
            1620.6062 14 N 5 539.1701 y5-NH3 522.1435         
    b15-NH3 1706.5888 a15 1695.6205 1723.6154 15 C 4 425.1272 y4-NH3 408.1006 y4-H2O 407.1166     
    a16-NH3 1781.6031 b16-NH3 1809.5980 1826.6246 16 C 3 322.1180 y3-NH3 305.0914 y3-H2O 304.1074     
            1940.6675 17 N 2 219.1088 y2-NH3 202.0822 y2-H2O 201.0982     
    
        --- 18 S 1 105.0659 






9. Conclusion  
This work has addressed the effect of different MS parameters on peptide fragmentation. One 
of the parameters that can be manipulated by the operator is the cone potential, which can 
affect the precursor ion charge state and fragmentation prior to the arrival of the charged 
analyte in the collision cell. By changing the cone voltage we managed to change the 
fragmentation pattern of a model peptide. But it is assumed that, its benefit is more 
pronounced when the fragmentation characteristics of the peptide is known to the operator.   
The most informative collision energy was found to be directly related to the m/z of the 
precursor ion. This optimal collision energy was also compared with the most informative 
collision energy ramps. In the present work, the results points to the superiority of collision 
energy ramp mode compared to single collision energy.   
Considering the complexity of peptide fragmentation characteristics in MS/MS, larger data 
sets are required to establish how the different factors affect the quality of a spectrum for de 
novo sequencing. It would be important to continue the project with a wide variety of peptides 
(having different m/z ratio, mass, charge state, amino acid sequence) to determine how the 
different MS parameters are related to the fragmentation of peptides.    
A software package, PEAKS studio 7, used for automated de novo sequencing was also tested 
for accuracy using model peptides having different characteristics (precursor ion charge, m/z 
and chain length). The software is found to be fairly accurate for smaller peptides, considering 
a good spectrum is chosen.  But it was found out that its precision diminishes with increasing 
peptide length.  
An unknown bioactive peptide was also sequenced using the software and 84% of the 
residues were correctly sequenced.   
Peaks can be an effective tool for the laborious and time consuming de novo sequencing 
work, especially for smaller peptides.  But for larger peptides, breaking it down by enzymes 
should be considered.  
Determining the cysteine residue crosslinking of the peptide which was not addresses in this 
paper due to time constrain is the next step toward understanding the structure of the 
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10. Appendix 1: Determining the effect of precursor ion m/z on collision energy needed for 
effective peptide fragmentation 
Tables a-e : Show sequence ions identified after Tertiapine, Endothelin, Neurotoxin, Defensing and 
Orexin-A were fragmented at collision energies ranging from 20 - 45 eV. The numbers in the table 
indicate the charge state of the fragment ions.   
 
Table a: Tertiapine [M+4H] 4+ = 615.3226 
The peptide fragments well at collision energies of 20 eV and 25 eV. The peptide loses the first two 
amino acids Ala-Leu probably in the ion source at a cone voltage of 35 V and produces an intense y 194+ 
(m/z= 569.2928, z=4),  this fragment was also dissociated  best at this collision energy range  
20eV 25 eV 30eV y-ion  b-ion 20eV 25 eV 30eV 
   21 A 1    
   20 L 2  (+1)  (+1)  
   19 C 3    
 (+3)  (+3)  18 N 4    (+1) 
 (+3)   17 C 5  (+1,2)  (+1,2)  
 (+3)   16 N 6  (+1,2)  (+1,2)  
   15 R 7  (+1,2)  (+1,2)  (+1,2) 
  (+2)  14 I 8  (+1,2)  (+1, +2)  (+2) 
 (+2)   13             I 9  (+2)  (+1, +2)  (+1,2) 
 (+2,3)  (+2)  12  I  10  (+1,2)  (+2)  
 (+2,3)  (+1,2,3)  11             P 11  (+2)  (+2)  
 (+2,3)  (+1,2,3)  (+2,3) 10   H 12  (+2)  (+2)  
 (+1,2)  ( +2)  (+2) 9   M 13  (+,2)   
 (+1,2)  (+1,2)  8               C 14  (+2)  (+2)  
 (+1)  (+1)  7                W 15  (+3)   
 (+1)  6  K 16  (+3)  (+2)  
 (+2)  (+1,2)  (+2) 5                 K 17  (+2)   
 (+1)  (+1)  4  C 18    
  (+1)  3  G 19    
  (+1)  2 K 20  (+3)  (+2)  





Table b: Endothelin [M+3H] 3+ = 850.7051. 
The peptide fragments well between 30 and 40 eV and 35 eV appears to be the optimum collision energy. The sequence 
ions are dominated by b-ions. 
20 eV 25 30 35 40 b-ions  y-ions 20 25 30 35 40 
 (+1)     1 C 21      
 (+1)   (+1)  (+1)  (+1) 2 S 20      
 (+1)    (+1)  (+1) 3 C 19      
  (+1)   (+1)  (+1) 4 S 18    (+2)   
  (+1)  (+1)   (+1) 5 S 17      
   (+1)  (+1)  (+1) 6 W 16      
  (+1)  (+1  (+1)  (+1) 7 L 15      
  (+1)  +1)  (+1)  (+1) 8 D 14    (+2)  (+2)  
 (+1)   (+1)  (+1)  (+1) 9 K 13      
  (+1)  (+1,2)  (+1)  (+1,2) 10 E 12      
 (+1)  (+1,2)  (+1,2)  (+2)  (+1,2) 11 C 11   (+1)  (+1)   
  (+1,2)  (+1,2)  (+1,2)  (+1,2) 12 V 10      
 (+2)  (+1,2)  (+1,2)  (+1,2)  (+1) 13 Y 9  (+2)  (+1)  (+1)   
  (+1,2)   (+1,2)  (+1,2) 14 F 8   (+1)  (+1)   
  (+1)  (+1)  (+1,2)  (+1,2) 15 C 7   (+1)    
  +1,2  (+1,2)  (+2)  (+2) 16 H 6   (+1)    
  (+2)  (+2)  (+2)  (+2) 17 L 5      
 (+2)  (+3)  (+2,3)  (+2)  (+2) 18 D 4      
 (+2,3)  (+2)  (+2)  (+2)  19 I 3  (+1)     
 (+2,3)  (+2)  (+2)  (+2)  20 I 2  (+1)  (+1)  (+1)  (+1)  (+1) 





Table-c: Neurotoxin [M+3H] 3+ = 979.3961 
Neurotoxin produces very intense y9 and y16
2+ ions and low intensity ions in the other m/z 
ranges with the collision energies under 30 eV (not indicated). All the other collision energies 
(30,35 and 40eV) have produced almost complete sequence ions. 35 eV was taken as 
optimum CE. 
30eV 35 V 40 eV b-ions  y-ions 30 eV 35eV 40eV 
   1 R 27    
   2 S 26    
 +1  +1  +1 3 C 25    
 +1  +1  +1 4 C 24    
   5 P 23  +2   
 +1  +1  +1 6 C 22    
 +1,2  +1,2  +2 7 Y 21  +2   
 +1,2  +1,2  +1, 2 8 W 20  +2   
 +1,2  +1,2  +2 9 G 19  +2  +2  
 +2  +1,2  +2 10 G 18  +2  +2  
  +1,2  +1,2 11 C 17    +2 
 +2  +2  +2 12 P 16  +1,2  +2  +2 
 +1,2  +1,2  +2 13 W 15   +1,2  +1 
 +2  +2  +2 14 G 14  +1,2  +2  +1 
 +1,2  +1,2  +1,2 15 Q 13  +1,2  +2  
 +2  +1,2  16 N 12  +2  +1,2  +1 
 +2  +2  +1 17 C 11  +1  +1  +1 
  +2  18 Y 10  +1,2  +1,2  +1, 2 
   19 P 9  +1,2  +1,2  +1,2 
   20 E 8  +1  +1  +1 
   21 G 7  +1  +1  +1 
 +2   22 C 6  +1  +1  +1 
   23 S 5  +1  +1  +1 
   24 G 4  +1  +1  +1 
   24 P 3  +1  +1  +1 
   26 K 2  +1  +1  +1 




       Table-d : Defensin [M+5H]5+ = 690.1198 
       Identified sequence ions of defensin. Collision energy of 35eV appears to be optimal.   
 
20eV 25eV 30eV 35eV 40eV b-ions   y-ions 20eV 25eV 30eV 35eV 40eV 
         1 A 30          
 (+2  +1    +1  +1 2 C 29          
     +1  +1  +1 3 Y 28          
         +1 4 C 27          
 +1,2  +1,2  +1  +1,2  +1 5 R 26      +3  +4  
 +1,2  +2     +1 6 I 25  +3    +3    
 +2  +2  +2  +1,2  +1 7 P 24  +3    +3    
 +2    +1   +1 8 A 23  +3  +3  +3  +3  
 +2    +2  +1  +1 9 C 22  +3  +3  +3    
 +2    +1  +1  10 I 21      +2  +3  
     +1,2    11 A 20        +2  
         +2 12 G 19          
   +1     13 E 18          
       +2  14 R 17  +3  +2    +3  
     +3  +3  15 R 16          
       +2  16 Y 15          
     +2  +3  17 G 14          
     +2  +2  18 T 13          
       +3  19 C 12          
         20 I 11      +1  +1  
        21 Y 10    +1  +1    
       +3  22 Q 9    +1  +1,
2 
 +1  
     +3  +3  23 G 8  +2      +1  
 +3    +3    24 R 7  +2        
 +3  +3  +3  +4  25 L 6          
   +3  +3  +4  26 W 5          
   +3  +3    27 A 4  +1        
   +3      28 F 3  +1  +1      
         29 C 2  +1  +1    +1  +1 













Table-e: Orexin-A [M+5H]5+ = 713.5572 
The peptide contains a modified glutamic acid at the N-terminus, pyroglutamic acid. Labeled as 
‘u’. Most of the observed sequence ions were at the higher m/z range of the spectrum. This might 
be because of the absence of the amino group at the N-terminus.  40eV seems to be the best 
collision energy.   
 
25eV 30 eV 35eV 40eV b-ions  y-ions 25eV 30 eV 35eV 40eV 
        1 u 33         
        2 P 32         
        3 L 31         
        4 P 30         
     (+2)   5 D 29         
        6 C 28         
        7 C 27         
       (+2) 8 R 26         
        9 Q 25         
        10 K 24         
        11 T 23         
       (+2) 12 C 22         
       (+2) 13 S 21         
       (+2) 14 C 20         
       (+2) 15 R 19         
       (+2) 16 L 18         
     (+2)   17 Y 17         
(+2) (+2)  (+2)  (+2,3) 18 E 16         
  (+2)  (+2,3)  (+2,3) 19 L 15         
(+2) (+2)  (+2,3)  (+2,3) 20 L 14         
(+3) (+2,3)  (+2,3)  (+2,3) 21 H 13         
(+3) (+2,3)  (+2,3)  (+2) 22 G 12         
(+3) (+2,3)  (+2,3)  (+2) 23 A 11         
(+3) (+2,3)  (+2,3)  (+2) 24 G 10         
  (+2,3)  (+2,3)  (+2,3) 25 N 9         
(+3) (+3)     26 H 8         
(+3) (+3)     27 A 7         
(+3) (+3)     28 A 6         
(+3) (+3)  (+3)   29 G 5         
(+3) (+3)     30 I 4         
(+3)       31 L 3  (+1)  (+1)     
     (+3)  (+3) 32 T 2  (+1)  (+1) (+1) (+1) 








After the peptides were fragmented by collision energy ramps of 20-30eV, 25-35eV, 25-40eV and 30-
40 eV, the collision energy ramps which produced larger number of sequence ions were selected as 
optimum collision energy ramp for that particular peptide. The peptides were fragmented at by their 
respective single collision energy (obtained from the above table) and the collision energy ramps. 
Comparison of optimum single collision energy (CE) and optimum collision energy ramps are given 
tables, f-l.  
 
Table-f:  Identified sequence ions of endothelin at optimum CE, 35 eV. 
 
Insilico m/z Observed 
m/z 









    1 C 21         
191,0485 191,0475 0,001 1.43e4 2 S 20         
294,0577 294,0588 -0,0011 2.66e3 3 C 19         
381,0897 381,088 0,0017 8.00e3 4 S 18         
468,1217 468,1122 0,0095 7.75e3 5 S 17         
654,201 654,2035 -0,0025 1.14e4 6 W 16         
767,2851 767,2867 -0,0016 8.12e3 7 L 15         
882,3121 882,3179 -0,0058 8.91e3 8 D 14 892,4128 892,4055 0,0073 1.12e4 
1010,407 1010,3972 0,0098 3.82e3 9 K 13         
1139,4496 1139,4484 0,0012 8.89e3 10 E 12         
621,733 621,7317 0,0013 1.79e3 11 C 11         
671,2672 671,2706 -0,0034 3.06e3 12 V 10         
1504,5905 1504,5885 0,002 5.23e3 13 Y 9         
        14 F 8         
1754,6681 1754,6859 -0,0178 3.26e3 15 C 7         
946,3672 946,372 -0,0048 3.55e4 16 H 6         
1002,9092 1002,9144 -0,0052 2.00e4 17 L 5         
1060,4227 1060,4259 -0,0032 3.28e5 18 D 4         
1116,9647 1116,9736 -0,0089 2.19e4 19 I 3         
1173,5067 1173,5079 -0,0012 3.51e3 20 I 2 318,1812 318,1811 0,00 5.9e45 










Table-g: Sequence ions of endothelin at optimum CE ramp (25-40 eV). The identified ions correspond to 
the sequence ions identified at the optimum CE.   
 













        1 C 21       Intensity 
191,0485 191,0495 -0,001 9.21e3 2 S 20         
294,0577 294,0554 0,0023 4.233e3 3 C 19         
381,0897 381,0898 -0,0001 5.58e3 4 S 18         
468,1217 468,1239 -0,0022 5.42e3 5 S 17         
654,201 654,2029 -0,0019 8.03e3 6 W 16         
767,2851 767,2867 -0,0016 6.79e3 7 L 15         
882,3121 882,3129 -0,0008 7.47e3 8 D 14 892,4128 892,4088 0,004 9.01e3 
1010,407 1010,4009 0,0061 3.39e3 9 K 13         
1139,4496 1139,4573 -0,0077 4.66e3 10 E 12         
621,733 621,7331 -0,0001 2.26e3 11 C 11         
1341,5272 1341,5264 0,0008 7.96e3 12 V 10         
752,7989 752,8015 -0,0026 2.20e3 13 Y 9         
        14 F 8         
1754,6681 1754,6775 -0,0094 2.95e3 15 C 7         
946,3672 946,3615 0,0057 2.23e4 16 H 6         
1002,9092 1002,9039 0,0053 2.13e4 17 L 5         
1060,4227 1060,4177 0,005 2.16e5 18 D 4         
1116,9647 1116,955 0,0097 1.45e5 19 I 3         
        20 I 2 318,1812 318,1808 0,0004 1.05e5 




Table-g: Identified sequence ion of conotoxin-α (z=2) at optimal CE, 35 eV. The ion y7 
shows very high intensity even at higher CE. This can be due to bond cleavage enhancement 



















        1 C 12         
161,0379 161,038 -0,0002 9.42e3 2 R 11         
264,0471 264,048 -0,0011 2.43e3 3 W 10         
        4 A 9         
        5 C 8         
        6 R 7 445,72 445,715 0,0004 1.36e5 
        7 P 6 397,19 397,1861 0,003 3.87e3 
        8 D 5 637,27 637,2726 -0,0029 2.28e4 
        9 S 4 534,26 534,2645 -0,004 4.78e3 
        10 C 3 463,22 463,2282 -0,0048 2.95e3 
        11 C 2 277,14 277,1473 -0,0032 3.12e3 
        12 G 1 121,04 121,0427 0,0003 4.89e3 
 
 
Table-h: Identified sequence ion of conotoxin-α (z=2) at its optimal collision energy ramp, 25-40 
eV. The ramp scan has produced two extra sequence ions (b5 and y10) compared to the optimum 
CE. 


















        1 C 12         
161,0379 161,0386 -0,0007 7.80e3 2 R 11         
264,0471 264,0463 0,0008 3.93e3 3 W 10 598,2495 598,2557 -0,0062 1.11e3 
        4 A 9         
466,1061 466,1129 -0,0068 1.74e3 5 C 8         
        6 R 7 445,7154 445,7152 0,0002 2.27e5 
        7 P 6 397,1891 397,1865 0,0026 5.19e3 
        8 D 5 637,2697 637,2685 0,0012 2.52e4 
        9 S 4 534,2605 534,2632 -0,0027 3.73e3 
        10 C 3 463,2234 463,2263 -0,0029 3.28e3 
        11 C 2 277,1441 277,148 -0,0039 2.94e3 


























        1 R 27         
        2 S 26         
347,15 347,1493 0,0003 4.75e3 3 C 25         
450,159 450,1584 0,0004 1.84e4 4 C 24         
        5 P 23         
650,221 650,2261 -0,0054 1.78e4 6 C 22         
813,284 813,2932 -0,0091 6.66e4 7 Y 21         
999,363 999,3729 -0,0095 5.03e4 8 W 20         
1056,38 1056,389 -0,0042 1.70e4 9 G 19 969,41 969,4163 -0,0081 3.54e3 
1113,41 1113,4131 -0,0068 1.45e4 10 G 18 940,9 940,905 -0,0075 1.23e3 
1216,42 1216,4248 -0,0093 1.34e5 11 C 17     0   
657,238 657,2416 -0,0038 1.78e4 12 P 16 860,88 860,8881 -0,006 1.03e5 
750,277 750,2791 -0,0017 8.60e3 13 W 15     0   
778,788 778,7959 -0,0077 1.14e4 14 G 14 719,32 719,3231 -0,007 2.83e3 
1684,63 1684,6316 -0,004 3.71e3 15 Q 13 690,81 690,801 0,0044 2.73e3 
        16 N 12 1252,5 1252,5558 -0,0109 4.18e4 
951,344 951,3513 -0,0078 1.35e4 17 C 11 1138,5 1138,5048 -0,0028 3.09e4 
1032,88 1032,8824 -0,0072 5.92e3 18 Y 10 518,25 518,252 -0,002 1.08e4 
        19 P 9 872,43 872,4369 -0,0074 1.92e5 
        20 E 8 775,38 775,3805 -0,0038 7.85e3 
        21 G 7 646,33 646,34 -0,0059 2.61e4 
        22 C 6 589,31 589,3135 -0,0009 5.07e3 
        23 S 5 486,3 486,3056 -0,0021 1.43e4 
        24 G 4 399,27 399,2715 0,0014 1.36e4 
        25 P 3 342,25 342,251 -0,001 1.25e4 
        26 K 2 245,2 245,1968 0,0004 1.76e3 
        27 V 1 117,1 117,1031 -0,0009 2.18e3 
59 
 
Table-J:  Sequence ions of neurotoxin at its optimum ramp (25-40 eV). More sequence ions 



















        1 R 27         
244,1404 244,1371 0,003 4.07e3 2 S 26         
347,1496 347,148 0,002 4.55e3 3 C 25         
450,1588 450,1582 0,001 4.66e4 4 C 24         
        5 P 23         
650,2207 650,2248 -0,004 1.53e3 6 C 22         
813,2841 813,2825 0,002 6.66e4 7 Y 21         
500,1853 500,1878 -0,002 9.93e3 8 W 20 1062,4 1062,4435 0,0044 1.05e4 
528,6961 528,6915 0,005 1.56e4 9 G 19 969,41 969,4011 0,0071 1.86e4 
557,2068 557,2049 0,002 2.40e4 10 G 18 940,9 940,8849 0,0126 5.22e3 
608,7114 608,7059 0,005 1.93e4 11 C 17 912,39 912,3826 0,0041 1.09e4 
657,2378 657,2333 0,005 1.74e4 12 P 16 860,88 860,8774 0,0047 1.52e5 
750,2774 750,2742 0,003 1.70e4 13 W 15     0   
778,7882 778,7852 0,003 1.82e4 14 G 14 719,32 719,312 0,0041 1.45e4 
842,8174 842,8091 0,008 1.12e4 15 Q 13 690,81 690,8033 0,0021 8.12e3 
899,8389 899,8371 0,002 1.67e4 16 N 12 626,78 626,7766 -0,0005 5.54e3 
951,3435 951,3354 0,008 3.17e4 17 C 11 1138,5 1138,4988 0,0032 3.12e4 
1032,875 1032,871 0,005 5.92e3 18 Y 10 518,25 518,2491 0,0009 1.42e4 
1081,402 1081,412 -0,010 1.12e3 19 P 9 436,72 436,7204 -0,002 3.65e4 
1145,923 1145,911 0,012 3.28e3 20 E 8 775,38 775,3733 0,0034 5.98e3 
1174,434 1174,43 0,003 2.17e3 21 G 7 646,33 646,329 0,0051 3.26e4 
        22 C 6 589,31 589,3105 0,0021 5.21e3 
        23 S 5 486,3 486,3022 0,0013 1.97e4 
        24 G 4 399,27 399,2707 0,0007 1.47e4 
        25 P 3 342,25 342,2502 -0,0002 1.70e4 
        26 K 2 245,2 245,1986 -0,0014 2.39e3 




Table-K: Identified sequence ions of tertiapine at optimum CE of 25 eV  


















        1 C 19         
218,059 218,0593 -0,0003 3.19e4 2 N 18 724,3826 724,3787 0,0039 6.60e3 
        3 C 17         
        4 N 16         
591,2126 591,2142 -0,0016 8.54e4 5 R 15         
704,2967 704,2991 -0,0024 1.40e5 6 I 14         
817,3807 817,3848 -0,0041 1.89e5 7 I 13         
930,4648 930,4698 -0,005 8.23e4 8 I 12 729,3882 729,3805 0,0077 1.09e4 
514,2624 514,2628 -0,0004 6.06e3 9 H 11 672,8461 672,8477 -0,0016 1.05e5 
582,7919 582,794 -0,0021 1.12e4 10 P 10 624,3197 624,3216 -0,0019 7.41e4 
648,3121 648,3141 -0,002 5.63e3 11 M 9 1110,573 1110,583 -0,0095 3.39e4 
699,8167 699,8221 -0,0054 6.23e3 12 C 8 979,5328 979,5342 -0,0014 3.13e4 
        13 W 7 876,5236 876,5258 -0,0022 9.17e3 
        14 K 6 690,4443 690,4473 -0,003 1.28e4 
        15 K 5 562,3494 562,3489 0,000 3.80e4 
        16 C 4 434,2544 434,2548 0,000 1.13e4 
        17 G 3 331,2452 331,2446 0,001 2.21e4 
    18 K 2 274,2238 274,223 0,001 6.27e3 




Table-L: Identified sequence ions of tertiapine at optimum CE ramp between 25 and 35 eV. Ion 
b17 was not identified when the peptide was fragmented at its optimal single collision energy. 




In silico Observed Deviation Intensity 
        1 C 19         
218,0594 218,0596 -0,0002 3.33e4 2 N 18 724,3826 724,3906 -0,0080 1.34e3 
        3 C 17         
        4 N 16         
591,2126 591,2143 -0,0017 1.29e5 5 R 15         
704,2967 704,2986 -0,0019 9.18e4 6 I 14         
817,3807 817,3839 -0,0032 7.81e4 7 I 13         
930,4648 930,4665 -0,0017 3.06e4 8 I 12 729,3882 729,3828 0,0054 1.15e3 
514,2624 514,2628 -0,0004 2.19e3 9 H 11 672,8461 672,845 0,0011 1.58e4 
582,7919 582,7923 -0,0004 3.99e3 10 P 10 624,3197 624,3214 -0,0017 1.62e4 
        11 M 9 555,7903 555,7932 -0,0029 6.04e3 
699,8167 699,8068 0,0099 1.07e3 12 C 8 979,5328 979,5291 0,0037 9.32e3 
        13 W 7 876,5236 876,5176 0,0060 3.29e3 
        14 K 6 690,4443 690,4464 -0,0021 6.91e3 
        15 K 5 562,3494 562,3488 0,0006 1.81e3 
        16 C 4 434,2544 434,2558 -0,0014 2.33e4 
448,8998 448,9001 -0,0003 5.23e3 17 G 3 331,2452 331,2448 0,0004 6.66e3 
        18 K 2 274,2238 274,2258 -0,0020 5.64e3 





Appendix 3:  
Table-M: Identified sequence ions (colored) of selectively alkylated conotoxin-α by NMM and NCM. The two structural 
isomers are presented side by side.  (Left) C2 and C12 of the peptide are bound to NMM. (right) C2 and C12 of the peptide are 
bound to NCM and in the same manner C3 and C12 are bound to NMM. y1, y2, y3, y10 and b2 and b8 are signature ions that 
can help us to differentiate the isomers.  b2, y1 and y10 were identified. 
      
 
 C2 & C12 -NMM ,  C3 &C8 - NCM 
 
C2 & C12-NCM, C3 & C12- NMM 
b b+2 




   
y y+2 
       
 
       
--- --- 1 G 12 --- --- 
 
--- --- 1 G 12 --- --- 
272.0700 --- 2 u 11 1878.7543 939.8808 
 
340.1326 --- 2 u 11 1878.7543 939.8808 
554.1738 --- 3 v 10 1664.7130 832.8602 
 
554.1738 --- 3 v 10 1596.6504 798.8289 
641.2058 --- 4 S 9 1382.6092 691.8083 
 
641.2058 --- 4 S 9 1382.6092 691.8083 
756.2327 --- 5 D 8 1295.5772 648.2922 
 
756.2327 --- 5 D 8 1295.5772 648.2922 
853.2855 --- 6 P 7 1180.5503 590.7788 
 
853.2855 --- 6 P 7 1180.5503 590.7788 
1009.3866 505.1969 7 R 6 1083.4975 542.2524 
 
1009.3866 505.1969 7 R 6 1083.4975 542.2524 
1291.4904 646.2489 8 v 5 927.3964 464.2018 
 
1223.4278 612.2176 8 v 5 927.3964 464.2018 
1362.5275 681.7674 9 A 4 645.2926 323.1499 
 
1294.4649 647.7361 9 A 4 713.3552 357.1812 
1548.6069 774.8071 10 W 3 574.2555 287.6314 
 
1480.5443 740.7758 10 W 3 642.3181 321.6627 
1704.7080 852.8576 11 R 2 388.1761 194.5917 
 
1636.6454 818.8263 11 R 2 456.2387 228.6230 
--- --- 12 u 1 232.0750 --- 
 
--- --- 12 u 1 300.1376 --- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
